Mr Mohan V Mundasad
F.R.C.S. (Edin), F.R.C.Ophth (London), D.O.R.C. S. (Dublin), R.S.C. (Europe), D.O.M.S.
From 1986 to 1993, Mr Mundasad worked at the Princess of Wales Hospital and
Eye Treatment Centre, Bridgend. Since then he has worked as a Clinical
Fellow and Hon. Research Fellow at the department of Ophthalmology,
University of Bristol. From 1996 he has been working as an Associate
Specialist at Bristol Eye Hospital.
In 1998 he was one of the very few who successfully completed the refractive
surgery course and examination held by the European Society of Cataract and
Refractive Surgeons in Nice.
He has successfully performed over 2000 laser treatments for refractive
errors and to date has completed over two thousand laser treatments in the
NHS for various eye conditions.
During 1984, he was the first eye specialist in Wales to use Botulinum Toxin
as a research drug to treat patients with Facial Dystonia, which has now
become an accepted way of treating various forms of Dystonia. He continues
to be actively involved in Clinical Research and has recently completed a
clinical trial for a new drug for dry eyes in collaboration with a
pharmaceutical Research Company in North Carolina. He presented research
findings at the ARVO Florida, on the new formulation to treat dry eyes
during 2000-2001 and a novel method of non invasive delivery of drugs during
May 2002. To date he has completed seventeen clinical trials for new drugs
in Ophthalmology.
Mr Mundasad is a member of British Society for Refractive Surgery, The
European Society of Cataract and Refractive Surgery, General Medical
Council, South West Ophthalmic Society, Royal College of Ophthalmologists
and Oxford Ophthalmological Congress.
Publications:
- Journal of Ocular Pharmacology and Therapeutics Number 2, 2003:
Tolerance of Ocular Iontophoresis in Healthy Volunteers
- Journal of Ocular Pharmacology and Therapeutics Number 2, 2001:
Ocular Safety of INS365 Ophthalmic Solution: A P2Y2 Agonist In Healthy Subject
- Lacrimal Gland , Tear film and Dry Eye Syndromes : Ocular Safety of INS365 Ophthalmic Solution in patients with mild to moderate dry eye disease
- EYE; February 2008- Evaluation of a new cataract surgery pathway.
- Br J Ophthalmol.2006; 90: 1328-1329
In vivo measurement of opacified H60M intraocular lenses using Scheimpflug
photography
|
